Capodanno, Davide
Bhatt, Deepak L. http://orcid.org/0000-0002-1278-6245
Eikelboom, John W.
Fox, Keith A. A. http://orcid.org/0000-0002-0140-2752
Geisler, Tobias
Michael Gibson, C. http://orcid.org/0000-0002-4857-9125
Gonzalez-Juanatey, Jose Ramon
James, Stefan
Lopes, Renato D.
Mehran, Roxana
Montalescot, Gilles
Patel, Manesh
Steg, P. Gabriel
Storey, Robert F.
Vranckx, Pascal
Weitz, Jeffrey I.
Welsh, Robert
Zeymer, Uwe
Angiolillo, Dominick J. http://orcid.org/0000-0001-8451-2131
Article History
Accepted: 18 November 2019
First Online: 17 January 2020
Competing interests
: D.C. has received speakers’ honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo and Pfizer, and consulting fees from Abbott Vascular, Bayer and Daiichi Sankyo. D.L.B. is on the Advisory Board of Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio and Regado Biosciences; is on the Board of Directors of Boston VA Research Institute, Society of Cardiovascular Patient Care and TobeSoft; is Chair of the AHA Quality Oversight Committee; is on the Data Monitoring Committees of Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo) and Population Health Research Institute; has received honoraria from the ACC (Senior Associate Editor, <i>Clinical Trials and News</i>, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, <i>Harvard Heart Letter</i>), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, <i>Journal of Invasive Cardiology</i>), <i>Journal of the American College of Cardiology</i> (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, <i>Cardiology Today’s Intervention</i>), Society of Cardiovascular Patient Care (Secretary/Treasurer) and WebMD (CME steering committees); he is involved in <i>Clinical Cardiology</i> (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair) and VA CART Research and Publications Committee (Chair); he has received research funding from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic and The Medicines Company; receives Royalties from Elsevier (Editor, <i>Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease</i>); is a site co-investigator at Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; is a trustee for ACC; and has performed unfunded research for FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma and Takeda. J.W.E. holds a mid-career award from the Heart and Stroke Foundation of Ontario, Canada, and the Jack Hirsh/Population Health Research Institute Chair in Thrombosis and Atherosclerosis; and has received honoraria and research support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, Janssen, Pfizer and Servier. K.A.A.F. has received grants from AstraZeneca, Bayer and Janssen; and speaker engagements and consulting fees from Bayer, Janssen, Regeneron, Sanofi and Vereseon. T.G. has received speaker fees from AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer and Daiichi Sankyo; and has received institutional research grants from Bayer AG, Bristol-Myers Squibb/Pfizer and Daiichi Sankyo; is a recipient of funding from the DFG (German Research Foundation) Klinische Forschergruppe 274 (Platelets — Molecular Mechanisms and Translational Implications and the Collaborative Research Center Transregio 240). C.M.G. is chief executive officer of the Baim Institute for Clinical Research, and has received research grant funding from Angel Medical Corp., Bayer Corp., CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson and Portola Pharmaceuticals; consultant fees from Amarin Pharama, Amgen, Bayer Corp., Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Cardiovascular Research Foundation, CSL Behring, Chiesi, Duke Clinical Research Institute, Eli Lilly and Company, Gilead Sciences, Inc., Impact Bio Ltd., Janssen Pharmaceuticals, Johnson & Johnson Corp., The Medicines Company, MedImmune, Medtelligence, Merck & Co., Inc., Microport, Novo Nordisk, PERT Consortium, Pharma Mar, Portola Pharmaceuticals, Sanofi, Somahlution, Vereseon Corporation and WebMD; and royalties as a contributor from <i>UpToDate in Cardiovascular Medicine</i>. J.R.G.-J. has received institutional research funding from Angem, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ferrer International, Medtronic, MDS, Novartis, Pfizer, Sanofi and Servier; and is a consultant to Bayer, Boehringer-Ingelheim and Amgen. S.J. has received institutional research grants and speaker honoraria from Abbot Vascular, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Jensen, The Medicines Company and Novo Nordisk. R.D.L has received consulting fees from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer and Sanofi; and has received institutional grants from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer and Sanofi. R.M. has received institutional research funding from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi Sankyo, Medtronic, Novartis and OrbusNeich; is a consultant to Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Regeneron Pharmaceuticals Inc. (no fees), Roivant Sciences Inc. and Sanofi; is an institutional consultant (payment to institution) with Abbott Vascular and Spectranetics/Phillips/Volcano Corporation; is on the executive committee for Bristol-Myers Squibb and Janssen Pharmaceuticals; and receives institutional (payment to institution) advisory board funding from Bristol-Myers Squibb, Novartis and Data Safety Monitoring Board membership funding to institution from Watermark Research; has <1% equity with Claret Medical and Elixir Medical. G.M. reports research grants to the Institution or consulting/or lecture fees from Abbott, ACC Foundation, Actelion, Amgen, AstraZeneca, Axis-Santé, Bayer, Beth Israel Deaconess Medical, Boston-Scientific, Boehringer Ingelheim, Brigham Women’s Hospital, Bristol-Myers Squibb, China heart House, Daiichi Sankyo, Idorsia, Elsevier, Europa, Fédération Française de Cardiologie, ICAN, Lead-Up, Medtronic, Menarini, MSD, Novo Nordisk, Partners, Pfizer, Quantum Genomics, Sanofi, Servier and WebMD. M.P. reports research grants to the Institution from AstraZeneca, Bayer, Heartflow, Janssen, NIH, Procyrion and Medtronic; and consulting or advisory board fees from Bayer, Janssen, Medscape and Amgen. P.G.S. reports research grants from Amarin, Bayer, Merck, Sanofi and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer-Ingelheim, Bristol-Myers Squibb, Idorsia, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi and Servier. R.F.S. reports research grants to the institution from AstraZeneca and PlaqueTec; consultancy fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, GlyCardial, Haemonetics, Idorsia, Novartis, PlaqueTec and Thromboserin; and speaker fees or honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer and Medscape. P.V. has received personal fees from AstraZeneca, Bayer HealthCare, CLS Behring and Daiichi Sankyo. J.I.W. has received institutional research funding from Bayer and Boehringer-Ingelheim and consultant fees and honoraria from Anthos, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ionis Pharmaceuticals, Pfizer, Portola, Janssen, Servier and Tetherex. R.W. reports research grants and honoraria from AstraZeneca, Bayer and Boehringer-Ingelheim; and honoraria from Amgen, Bristol-Myers Squibb/Pfizer and Eli Lilly. U.Z. reports research grants from AstraZeneca, Bristol-Myers Squibb, Novartis and Eli Lilly; and speakers fees or honoraria from Abiomed, AstraZeneca, B. Braun, Bayer, Biotronik, Boehringer-Ingelheim, Bristol-Myers Squibb, Correvio, Daiichi Sankyo, Eli Lilly, Ferrer, Medtronic, Medicines Company, MSD, Novartis, Pfizer, Sanofi and Trommsdorf. D.J.A. has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi and The Medicines Company; has received payments for participation in review activities from CeloNova and St Jude Medical; his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry, Merck, Novartis, Osprey Medical and Renal Guard Solutions.